Gylden’s 2025 Strategic Priorities for Advancing Innovative and Transformative Solutions for Infectious Diseases
Clinical trials planned to begin patient enrollment during 2025 to [...]
Emergex Announces Company Name Change to “Gylden Pharma Limited” Reflecting Company’s Commitment to Advanced Core Technologies and Expanded Product Pipeline
Abingdon, United Kingdom, 17 October 2024 – Emergex Vaccines Holding Limited, [...]
Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
- NIAID will be conducting and sponsoring clinical trials to [...]
Emergex Receives Patent Protection for First-in-Class Influenza A Vaccines with Potential to Provide Long-Term T Cell Immunity
- Breakthrough patent represents a significant leap in influenza pandemic [...]
Emergex Announces MHRA Approval of MIA (IMP) Manufacturing and Import Authorisation License
Abingdon, United Kingdom, 18 June 2024 – Emergex Vaccines Holding Limited [...]
Emergex Announces R&D Collaboration with DEKA Research & Development Corp. for Assessment of Emergex’s Immunotherapeutic Candidates with DEKA’s Intradermal Therapeutic Applicator
- Emergex has entered into an agreement with DEKA Research [...]
Emergex Announces Authorisation from Philippines FDA to Initiate Phase I-II Clinical Trial of CoronaTcP™
- Emergex received authorisation from the Philippines FDA to launch [...]
Successful Transfer of New Drug Application (NDA), Acknowledged by U.S. FDA, from Former Zosano Pharma to Emergex for Investigational Microneedle-Based Drug Delivery Patch
- Earlier this year, Emergex submitted a notification to the [...]
Emergex Signs Contract of £1,79M with the UK Department of Health and Social Care’s UK Vaccine Network (“UKVN”) to Advance Its Novel Synthetic T Cell-Priming Set-Point Candidate Against Chikungunya Virus
Abingdon, United Kingdom, 17 November 2023 – Emergex Vaccines Holding [...]
Emergex and Saudi Arabia’s Vaccine Industrial Company (VIC) have signed MoU to Advance First-of-its-Kind Infectious Disease Solutions
- Emergex and VIC plan to collaborate to further develop [...]